background: Corticotropin-releasing hormone (CRH) and its receptors have been identified in female reproductive tissues. CRH regulates follicular maturation, ovulation, luteolysis and steroidgenesis. A CRH-related peptide stresscopin (SCP), or urocortin III (Ucn3), has recently been identified, but its functions in the ovary remain to be elucidated. In the present study, we investigated the effects of SCP/Ucn3 on progesterone production in cultured human granulosa-lutein cells. conclusions: The present results suggest that the SCP/CRHR2 system is present in human ovaries and treatment with SCP/Ucn3 inhibits progesterone production by cultured granulosa-lutein cells through interaction with CRHR2.
Introduction
Corticotropin-releasing hormone (CRH), a neuropeptide of 41 residues, was first discovered based on its ability to promote anterior pituitary adrenocorticotropin release and is believed to play a major role in the body's response to stress. The CRH family of hormones comprises CRH, urocortin I (Ucn1), stresscopin (SCP)/urocortin III (Ucn3) and SCP-related peptide (SRP)/urocortin II (Ucn2). The CRH peptide family bind with different affinity to two distinct receptors, CRH receptor-type 1 (CRHR1) and -type 2 (CRHR2) (Donaldson et al., 1996; Hsu and Hsueh, 2001 ; Lewis et al., 2001; Reyes et al., 2001) . CRH displays high affinity for CRHR1, whereas Ucn1 has lower affinity to this receptor. Ucn1 displays high affinity for CRHR2, whereas CRH has lower affinity for this receptor. In contrast, SCP/Ucn3 and SRP/Ucn2 exclusively bind to CRHR2 (Hsu and Hsueh, 2001 ; Lewis et al., 2001; Reyes et al., 2001) . Human Ucn3 is a 38 amino acid peptide that corresponds to residues 3-40 of human SCP (Takahashi et al., 2004a) . The difference between SCP and Ucn3 lies in the post-translational processing site and therefore the amino acid sequences of the peptides differ only slightly (Takahashi et al., 2004a) . The studies on mice deficient for CRHR1 or CRHR2 have demonstrated that CRHR1 and CRHR2 have antagonistic effects on stress responses (Smith et al., 1998; Bale et al., 2000) . Recently, Ucn1, SRP/Ucn2 and SCP/Ucn3 were studied with regard to their roles in adaptive responses during the recovery from stress (Hsu and Hsueh, 2001 ; Lewis et al., 2001; Reyes et al., 2001; Xu et al., 2006) . SCP/Ucn3 is expressed in discrete brain areas, including the hypothalamus and amygdala (Hsu and Hsueh, 2001 ; Lewis et al., 2001) . The hypothalamic -pituitary -adrenal axis is a major component of the stress response (Lunga and Herbert, 2004) and is responsible for menstrual disorders, such as hypothalamic amenorrhea of stress, which is associated with anxiety and depression, malnutrition, eating disorders and chronic excessive exercise (Kalantaridou et al., 2003) . CRHR2 is important for stress-coping responses, including dearousal, sustained hypophagia, reduced blood pressure during the recovery phase of stress and the avoidance of damage incurred by excessive exposure to the 'fight or flight' responses initiated by the activation of pituitary CRHR1 (Smith et al., 1998; Bale et al., 2000) .
CRH has been thought to regulate key reproductive functions associated with an inflammatory component such as ovulation, luteolysis, implantation and parturition (Chrousos, 1995; Vitoratos et al., 2006) . CRH and its receptors have been identified in the female reproductive tissues, including the ovary, uterus and placenta. In the human ovary, CRH has been found in the cytoplasm of theca cells, luteinized cells of the stroma, large granulosa-derived luteinized cells of the developing corpus luteum and in human follicular fluid. CRH was shown to exert an inhibitory effect on ovarian steroidogenesis in cultured human granulosa cells (Calogero et al., 1996; Ghizzoni et al., 1997) . CRHR1 is expressed in the stroma, theca cells and the cumulus oophorus (Mastorakos et al., 1993; Mastorakos et al., 1994) . CRHR2 was also found to be present in the human ovary (Muramatsu et al., 2001) . The mRNA of a newly identified SCP/ Ucn3 was observed in many human tissues including the ovary (Hsu and Hsueh, 2001) , and immunoreactive SCP/Ucn3 protein has been detected in the endometrium, pancreas, heart, kidney and colon (Takahashi et al., 2004b; Saruta et al., 2005; Florio et al., 2006; Li et al., 2007) . Nevertheless, the role of SCP/Ucn3 in the ovary is poorly understood.
The present study was conducted to investigate whether SCP/ Ucn3 and its receptor CRHR2 were expressed in cultured human granulosa-lutein cells. The effects of SCP/Ucn3 on progesterone production by cultured human granulosa-lutein cells were also examined.
Materials and Methods

Clinical materials
Granulosa-lutein cells and follicular fluids were obtained from 21 infertile women (aged from 22 to 36 years) due to uni-or bilateral tubal impatency or male factor infertility. Patients were given daily injections of 300 IU hMG (Fuji Pharmaceutical, Tokyo, Japan) until at least three follicles reached 18 mm in diameter, at which time 5000 IU hCG (HCGMochida, Mochida Pharmaceutical, Tokyo, Japan) was administered. Oocyte retrieval was carried out 35.5 h after hCG injection under an intravenous anesthesia. In addition, ovarian tissues were obtained from patients with regular menstrual cycles who underwent hysterectomy with bilateral salpingo-oophorectomy for early staged cervical cancer. The institutional review board of Kobe University Hospital approved the use of human granulosa-lutein cells and ovarian tissues in the present study. Informed consent from each patient was obtained before the collection of specimens.
Cell cultures
After oocyte recovery, granulosa cells were collected from the follicular fluid by centrifugation at 72 g for 15 min. The cells were resuspended with a 1:1 mixture of medium 199 and Hanks' salt solution (Invitrogen Life Technologies, Grand Island, NY, USA), and pooled samples were prepared from each patient. The cell suspension (10 ml) was layered in 10 ml of lymphocyte separation medium (Ficoll, ICN Biomedicals) and centrifuged at 1800 rpm at room temperature for 30 min to separate the red blood cells (Ghizzoni et al., 1997) . Granulosa cells were recovered from the Ficoll interface, washed three times with Hanks' salt solution and resuspended in 3 ml of medium 199. Aliquots of the cell suspension were counted with a hemacytometer to determine the number of cells before plating (5 Â 10 5 cells/well) in multiwell dishes (BD Biosciences, Oxnard, CA, USA). Cultures were maintained in 1 ml of medium 199 with Earle's salt supplemented with 2% L-glutamine, 1% non-essential amino acids, 1% penicillin -streptomycin and 10% fetal bovine serum for incubation under 5% CO 2 at 378C (Ghizzoni et al., 1997) . After 24 h in culture, medium was replaced with 1 ml of serum-free medium, and cells were cultured for additional 24 h with the following conditions: medium alone (control) and medium containing CRH and SCP/Ucn3 (Phoenix Pharmaceuticals Inc., Belmond, CA, USA) in the presence or absence of a CRHR2 antagonist antisauvagine-30 (1 mM, Phoenix Pharmaceuticals Inc., Belmond, CA, USA). Culture media were collected 24 h later and stored at 2808C until assay for progesterone.
Total RNA extraction and RT-PCR
Total RNA was isolated from cultured granulosa-lutein cells (at 24 h) and whole ovarian specimens using RNeasy Micro Kit (Qiagen, Hilden, Germany). First-strand complementary DNA (cDNA) was synthesized from 4 mg of total RNA using a Transcriptor First-Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany) before amplification of the cDNA with a Gene Amp PCR System 9600-R (PerkinElmer, Norwalk, CT, USA). The primers (all listed as upstream, then downstream) used were as follows: cRH 5 0 . Amplification conditions for CRH, SRP/ Ucn2, SCP/Ucn3 and CRHR2 were as follows: denaturation at 948C for 30 s, annealing at 558C for 30 s and extension at 728C for 30 s. The reactions were subjected to 32 cycles. All the amplified products were separated in 2.0% agarose gels and the bands were visualized with ethidium bromide staining. Distilled water was used as a negative control for all of the reactions in place of the cDNA. The resultant PCR products were cloned into TA cloning vector (Invitrogen, San Diego, CA, USA) and sequenced (Bio Matrix Research, INC, Chiba, Japan). The sequence data were analyzed using Blast Nucleic Acid Database Searches from the National Center for Biotechnology Information.
Immunocytochemical analyses
The slides with 48 h-cultured granulosa-lutein cells were washed three times in phosphate-buffered saline, followed by incubation in 3% hydrogen peroxide/70% methanol to quench any endogenous peroxidase activity. Slides were incubated overnight at 48C with the primary anti-human peptide antibodies; 1:1000 for SCP/Ucn3 provided by Professor Wylie Vale (Salk Institute for Peptide Biology, La Jolla, CA, USA) and 1:50 for CRHR2, sc-20550 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The negative control was obtained by using the antibody preabsorbed with corresponding blocking peptides at a concentration of 20 mg/ml; SCP/Ucn3 (Sigma-Aldrich Corp., Tokyo, Japan), CRHR2, sc-12382 (Santa Cruz Biotechnology). The slides were then incubated with the appropriate secondary antibodies and processed using a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA, USA). Thereafter, chromogenic reaction was developed by incubation with the 3,3 0 -diaminobenzidine substrate Kit (Vector Laboratories, Inc., Burlingame, CA, USA). The cells were counterstained with Harris hematoxylin.
Radioimmunoassay for SCP/Ucn3
Serum was obtained from 10 healthy women (age ranging from 22 to 36 years, and stage of menstrual cycle not determined) without hMG -hCG treatment for the radioimmunoassay (RIA) experimental control. Concentrated serum-free culture media were collected from five individual patient's granulosa-lutein cell cultures. Cultures (1 Â 10 7 cells/well) in the multiwell dishes were maintained in medium containing serum. After 24 h culture, medium was replaced with 0.5 ml of serum-free medium, and cells were cultured for additional 24 h. Serum-free culture media were collected and stored at 2808C until assay for SCP/Ucn3. After oocyte retrieval, follicular fluid from dominant follicles was collected from 18 patients. SCP concentrations in each serum and follicular fluid sample, and in serum free culture media, were determined using Stresscopin RIA kit (Phoenix Pharmaceuticals Inc., Belmond. CA, USA). Briefly, samples were incubated with rabbit anti-SCP antiserum at 48C for 16 -24 h. 125 I-SCP was added to each sample as a radioligand, followed by further 16 -24 h incubation at 48C. The immune complex was precipitated by adding goat anti-rabbit immunoglobulin (Ig)G and normal rabbit serum. After incubation (90 min) at room temperature, samples were centrifuged at 1700g for 20 min and the supernatant was separated. The pellets were counted by g-counter before determination of SCP concentrations.
Enzyme-linked immunosorbent assay for progesterone
Cultures [5 Â 10 5 cells/well, pooled granulosa-lutein cells from at least three patients for one enzyme-linked immunosorbent assay (ELISA)] in the multiwell dishes were maintained in serum-free conditioned medium. Samples of serum-free conditioned medium after 24-h culture of granulosa-lutein cells were obtained. The quantification of progesterone concentration in media were determined using an ELISA kit (Alpha Diagnostic, San Antonio, TX, USA). Briefly, the standards and diluted samples were incubated with progesterone antibody and progesterone-horseradish peroxidase (HRP) conjugate in the anti-mouse IgG coated wells. The antibody-bound progesterone remained in the well, while unbound progesterone was removed by washing. Color development at OD 450 for each sample was measured after incubation with the HRP substrate for the determination of progesterone concentrations.
Statistical analysis
Results were expressed as the mean + SEM of three independent experiments. Statistical analyses were carried out by one-or two-way analysis of variance and post-hoc Tukey test. P-value of ,0.05 was considered to be significant.
Results
RT-PCR analysis of CRH, SRP/Ucn2, SCP/ Ucn3, CRHR2b mRNAs in the human ovary mRNA expression of CRH, SRP/Ucn2, SCP/Ucn3 and CRHR2b in the human ovary was examined by RT -PCR using specific primers. A 122-bp band corresponding to CRH, 196-bp band to SRP/Ucn2, 237-bp band to SCP/Ucn3 and 126-bp band to CRHR2b were observed in the human ovary (Fig. 1A) . The identity of all products was confirmed by sequencing.
RT-PCR analysis of SCP/Ucn3 and CRHR2b mRNAs in cultured human granulosa-lutein cells
RT -PCR analysis of granulosa-lutein cells after 24 h in culture was performed using the specific primers. A 237-bp band corresponding to SCP/Ucn3, and 126-bp band to CRHR2b were detected in cultured human granulosa-lutein cells (Fig. 1B) and their identity was confirmed by sequencing.
Immunocytochemical analysis of SCP/Ucn3 and CRHR2 in cultured human granulosa-lutein cells CRHR2 protein was measured in cultured granulosa-lutein cells after 24 h incubation in serum-containing medium using specific antibodies. Immunostaining for SCP/Ucn3 was detected in the cultured cells (Fig. 2 , upper left panel) and this was abolished by pre-incubation of the antiserum with synthetic SCP/Ucn3 peptide (Fig. 2 , upper right panel). CRHR2 was also immunostained in cultured granulosa-lutein cells using specific antibodies (Fig. 2, lower left panel) . Replacement of the primary antibody with the CRHR2 blocking peptide resulted in no immunostaining (Fig. 2, lower right panel) .
Ria of SCP/Ucn3 in the conditioned medium from cultured granulosa-lutein cells, human follicular fluid and serum SCP/Ucn3 was detectable in the concentrated conditioned media from cultured granulosa-lutein cells at the level of 98.2 + 6.81 pM (n ¼ 5), suggesting that SCP/Ucn3 is secreted by these cells. (Table I) , which was consistent with the previous result of 51.8 + 16.0 pM (Takahashi et al., 2004b) .
Effect of SCP/Ucn3 treatment on progesterone levels in cultured granulosa-lutein cells ELISA analysis revealed that treatment of granulosa-lutein cells in culture with SCP/Ucn3 at 0.1, 1.0 and 10 nM significantly (P , 0.05) attenuated the level of progesterone secretion to 79.4 + 6.1% (n ¼ 3), 74.2 + 3.1% (n ¼ 3) and 70.8 + 4.3% (n ¼ 3), respectively, compared with untreated controls (Fig. 3) . To explore whether the SCP/Ucn3-induced decrease in progesterone levels was mediated through CRHR2, cells were incubated with both 1.0 nM SCP/Ucn3 and 1 mM antisauvagine-30 (AS), a CRHR2 antagonist (Tu et al., 2007) . Concomitant treatment with SCP/Ucn3 and AS caused a significant (P , 0.05) recovery of progesterone levels, to 93.5 + 3.4% (n ¼ 3) of those seen with 1.0 nM SCP/Ucn3 alone (Fig. 3) . Treatment with 1 mM AS alone did not affect the progesterone levels in cultured granulosa-lutein cells, being 94.2 + 8.5% (n ¼ 3) of those seen in untreated controls (Fig. 3) .
Discussion
In this study, we demonstrated for the first time the presence of SCP/ Ucn3 mRNA and peptide in human granulosa-lutein cells by RT-PCR, immunocytochemistry and RIA. Inhibition of progesterone production was observed by the treatment of cultured human granulosa-lutein cells with SCP/Ucn3. The expression of human SCP/Ucn3 mRNA is demonstrated in various tissues such as the brain, heart, kidney, colon, pancreas and ovary (Hsu and Hsueh, 2001) . SCP/Ucn3 protein is expressed in human heart, kidney (Takahashi et al., 2004a) , colon (Saruta et al., 2005) and pancreas (Li et al., 2003) . SCP/Ucn3 plays an autocrine or paracrine role in these tissues. In rat, SCP/Ucn3 is induced cardiomyocytes by hypoxic stress and has a role as an anti-apoptotic factor (Chanalaris et al., 2003) . In the mouse pancreas, SCP/Ucn3 secreted from beta-cells acting through CRHR2 is involved in the local up-regulation of glucagon and insulin secretion (Li et al., 2003) . The functions of SCP/Ucn3 in other peripheral tissues still remain to be elucidated. For female reproductive functions, CRHR2 mediates, at least in part, restraint stress-induced inhibition of LH pulses and may play a role in the normal physiological response of stress-induced suppression of the hypothalamic GnRH pulse generator (Li et al., 2005) . Thus far, several investigators reported the immunolocalization of CRH family peptides and their receptors in the ovary. In human mature follicles, CRH and CRHR1 were shown to be localized in the theca cells (Mastorakos et al., 1994; Asakura et al., 1997; Muramatsu et al., 2001) . Asakura et al. (1997) suggested granulosa cells were devoid of CRH and CRHR1, but Muramatsu et al. (2001) demonstrated immunolocalization of CRH and CRHR1 in granulosa cells. In the human corpus luteum, CRH and CRHR1 were shown to be immunolocalized in the luteinized granulosa cells and luteinized theca cells (Muramatsu et al., 2001) . CRH was detected in normal human follicular fluid at a concentration of 4.975 + 1.179 pM (Mastorakos et al., 1994) . CRH suppressed steroidogenesis in the granulosa-lutein cells (Calogero et al., 1996; Ghizzoni et al., 1997) . In the primate, SRP/Ucn2 mRNA was detected in the ovary, but no SCP/Ucn3 mRNA expression was noted (Xu et al., 2006) . SRP/ Ucn2 peptide in the primate ovary was detected in granulosa cells of the parental, pre-ovulatory and atretic follicles, whereas the presence of CRHR1 and CRHR2 was not obvious (Xu et al., 2006) . In contrast, CRHR2 mRNA was shown to be expressed in the human ovary (Muramatsu et al., 2001) . In the present study, we demonstrated SCP/Ucn3 and CRHR2 in cultured human granulosa-lutein cells. The inconsistency of SCP/Ucn3 expression between the primate and human ovary may be a result of species differences. Moreover, our data confirmed SCP/Ucn3 production in human granulosa-lutein cells in vitro and the presence of SCP/Ucn3 in follicular fluid, which was probably secreted by granulosa cells in vivo. The expression of SCP/Ucn3 and CRHR2 in the ovary suggested that SCP/Ucn3 locally produced in granulosa-lutein cells may act as an autocrine or paracrine regulator to suppress progesterone production. However, the precise physiological role of SCP/Ucn3 in the menstrual cycle, and the interaction between hMG -hCG treatment and the production of SCP/Ucn3, remain to be elucidated. Further studies will be necessary in order to estimate the concentrations of SCP/Ucn3 in follicular fluid and serum at different stages of the menstrual cycle, with or without hMG -hCG treatment.
At mid menstrual cycle, low levels of progesterone delivered from the maturing follicle contribute to the precise synchronization of the midcycle LH surge (Liu and Yen, 1983 ). Modification of the low level of progesterone production in the ovary could be mediated partly by the effects of SCP/Ucn3 in an autocrine or paracine manner. On the other hand, SCP/Ucn3 overexpression by the stress responses could affect progesterone production in the ovary. During the mid menstrual cycle, the levels of progesterone are never high, but progesterone is an essential mediator of ovulation in all mammalian species (Chaffin and Stouffer, 2002) . Ovulation seems to be regulated by both estrogen and progesterone and not solely by estrogen (Batista et al., 1992) . Physiological and even supraphysiological levels of estradiol were not capable of inducing a LH -FSH surge, while progesterone was presumably blocked. Thus, increasing amounts of progesterone released by the mature follicle at midcycle appear to be the ultimate ovarian trigger of the gonadotrophin surge that leads to ovulation (Batista et al., 1992) . Progesterone is also a local regulator of the ovulatory process in rodents, acting through a receptor-mediated autocrine/paracrine pathway on the periovulatory follicle. And blockade of midcycle progesterone synthesis or activity by a progesterone synthesis inhibitor in primates impaired the ovulatory process and luteinization (Hibbert et al., 1996) . Moreover, administration of a potent antiprogesterone, RU486, induced different degrees of menstrual irregularities such as anovulation, delayed ovulation and a short luteal phase (Remohi et al., 1988) . To the best of our knowledge, there has been no relevant reference to support the direct correlations between ovarian dysfunction of patients and aberrant ovarian SCP/Ucn3 levels. But it is possible that ovarian dysfunctions and menstrual disorders of patients may correlate with aberrant ovarian SCP/Ucn3 levels.
In the present study, we demonstrated a role for SCP/Ucn3 as an autocrine or paracrine factor in the regulation of granulosa-lutein cell function, acting through CRHR2 to suppress ovarian progesterone secretion. Progesterone production by granulosa cells is also regulated by a number of growth factors such as thyroid hormone (Maruo et al., 1987) , insulin, insulin-like growth factor-I (Maruo et al., 1988) and epidermal growth factor (Maruo et al., 1993) . Thus, further studies on the interaction of SCP/Ucn3 with growth factors are necessary for a better understanding of the biological relevance of SCP/Ucn3 in the regulation of human granulosa-lutein cell function.
